Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes

What Was Tested

Researchers studied Insulin Aspart and Insulin Lispro in this randomized controlled trial publication.

Who Took Part

By PubMed's age tags, the people studied were children, teenagers, young adults, adults, middle-aged adults and older adults.

In this 13-week, multicenter, randomized trial, the researchers randomly assigned in a 2:1 ratio persons at least 6 years of age with type 1 diabetes either to receive bionic pancreas treatment with insulin aspart or insulin lispro or to receive standard care (defined as any insulin-delivery method with unblinded, real-time continuous glucose monitoring).

How the Study Was Run

In design terms this was a randomized and multicenter study.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Running at several centres spread the Insulin Aspart study over different clinics and patient groups.

The primary outcome was the glycated hemoglobin level at 13 weeks.

What Was Measured

Topics PubMed links to this paper include Bionics, Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 1, Glycated Hemoglobin, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized and multicenter study of Insulin Aspart and Insulin Lispro.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (The New England journal of medicine), a journal based in United States.

More context: the Insulin Aspart compound page and the Insulin Lispro compound page.